Evidence map›Paper›PMID 40719054›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2025

Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Following BCMA CAR T Failure

Bilal Kazi, Al-Ola A Adallah, Vijay Patil, Prashant Tembhare, Imaan Rumani, Marzooka Nazim Chishti Kazi

Abstract read
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bilal KaziPD Hinduja National Hospital and Medical Research Centre, Bone Marrow Transplantation, and Cellular Therapy, Department of Hematology, Mumbai, IndiaORCID 0009-0000-8071-6268
Al-Ola A AdallahUniversity of Kansas Medical Center, Plasma Cell Disorder Program, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United StatesORCID 0000-0002-6603-185X
Vijay PatilPD Hinduja National Hospital and Medical Research Centre, Department of Medical Oncology and Cellular Therapy, Mumbai, IndiaORCID 0000-0002-7691-3995
Prashant TembhareAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Department of Hematopathology, Navi Mumbai, IndiaORCID 0000-0002-9030-0415
Imaan RumaniSpecialty Surgical Oncology Hospital, Department of Oncosurgery, Ghatkopar, IndiaORCID 0000-0001-9969-1128
Marzooka Nazim Chishti KaziYB Chavan College of Pharmacy, Department of Pharmaceutics, Aurangabad, IndiaORCID 0000-0002-6103-7806

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BCMA CAR TMultiple myelomaSecondary plasma cell leukemiaTeclistamab

Identifiers

PMID40719054
PMCPMC12671262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.